RT Journal Article
SR Electronic
T1 Post-treatment downregulation of type III interferons in patients with acute Brucellosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.17.21255534
DO 10.1101/2021.04.17.21255534
A1 Mehran Shokri
A1 Oreinab Ghaffari Khonakdar
A1 Mousa Mohammadnia-Afrouzi
A1 Mahmoud Sadeghi-Haddad-Zavareh
A1 Amirhossein Hasanpour
A1 Mohammad Barary
A1 Soheil Ebrahimpour
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.17.21255534.abstract
AB There is a limited number of clinical studies on interferon (IFN) levels in human brucellosis. The novel group of interferons, type III interferons, consists of four IFN-λ (lambda) molecules called IFN-λ1 or Interleukin-29 (IL-29), IFN-λ2 or IL-28A, IFN-λ3 or IL-28B, and IFN-λ4, are not fully known. This study is one of the first studies of IL-28A and IL-29 levels in Brucellosis cases at the end of their treatment course. A total of 33 acute Brucellosis patients were included in this study. We considered changes in the levels of IL-28A and IL-29 in cases with acute brucellosis before and after treatment with standard therapy that referred to the Ayatollah Rohani Hospital in Babol, Northern Iran. Serum IL-29 and IL-28A (acute form: 56.4 ± 30.32 and 48.73 ± 27.72, respectively, and post-treatment: 40.15 ± 20.30 and 38.79 ± 22.66, respectively) levels were elevated significantly in acute brucellosis than after treatment (p ≤ 0.05). These findings indicate that considering biomarker levels in Brucellosis patients may be indicative of the chronicity of infection. In conclusion, we suggest that IL-29 and IL-28A levels may be valuable biomarkers for follow-up patients with brucellosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was fully supported by the vice-chancellor for research and technology of Babol University of Medical Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study protocol was approved by the ethics committee of Babol University of Medical Sciences (IR.MUBABOL.HRI.REC.1397.212).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.